Targeting Glutamatergic Signaling and the PI3 Kinase Pathway to Halt Melanoma Progression-Reference-Cited by-同舟云学术

Targeting Glutamatergic Signaling and the PI3 Kinase Pathway to Halt Melanoma Progression

Published:2015-02 Issue:1 Volume:8 Page:1-9
ISSN:1936-5233
Container-title:Translational Oncology
language:en
Short-container-title:Translational Oncology

Author:

Rosenberg Stephen A.,Niglio Scot A.,Salehomoum Negar,Chan Joseph L.-K.,Jeong Byeong-Seon,Wen Yu,Li Jiadong,Fukui Jami,Chen Suzie,Shin Seung-Shick,Goydos James S.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference45 articles.

1. Cancer Facts & Figures 2014;American Cancer Society,2014

2. Treatment for metastatic malignant melanoma: old drugs and new strategies;Mouawad;Crit Rev Oncol Hematol,2010

3. High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update;Atkins;Cancer J Sci Am,2000

4. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma;Chapman;J Clin Oncol,1999

5. Improved survival with ipilimumab in patients with metastatic melanoma;Hodi;N Engl J Med,2010

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Riluzole Suppresses Growth and Enhances Response to Endocrine Therapy in ER+ Breast Cancer;Journal of the Endocrine Society;2023-08-28

2. A phase I trial of riluzole and sorafenib in patients with advanced solid tumors: CTEP #8850;Oncotarget;2023-04-10

3. The role of glutamate receptors in the regulation of the tumor microenvironment;Frontiers in Immunology;2023-02-01

4. HER2 Mediates PSMA/mGluR1-Driven Resistance to the DS-7423 Dual PI3K/mTOR Inhibitor in PTEN Wild-type Prostate Cancer Models;Molecular Cancer Therapeutics;2022-01-27

5. The role of PI3'‐lipid signalling in melanoma initiation, progression and maintenance;Experimental Dermatology;2021-11-09